A promising future in cancer immunotherapy: Oncolytic viruses.

CAR-T therapy Cancer treatment Immunotherapy Oncolytic virus Targeted therapy Tumor microenvironment

Journal

European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354

Informations de publication

Date de publication:
05 Dec 2023
Historique:
received: 09 06 2023
revised: 18 09 2023
accepted: 19 09 2023
medline: 27 11 2023
pubmed: 6 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Alongside the conventional methods, attention has been drawn to the use of immunotherapy-based methods for cancer treatment. Immunotherapy has developed as a therapeutic option that can be more specific with better outcomes in tumor treatment. It can boost or regulate the immune system behind the targeted virotherapy. Virotherapy is a kind of oncolytic immunotherapy that investigated broadly in cancer treatment in recent decades, due to its several advantages. According to recent advance in the field of understanding cancer cell biology and its occurrence, as well as increasing the knowledge about conditionally replicating oncolytic viruses and their destructive function in the tumor cells, nowadays, it is possible to apply this strategy in the treatment of malignancies. Relying on achievements in clinical trials of oncolytic viruses, we can certainly expect that this therapeutic perception can play a more central role in cancer treatment. In cancer treatment, combination therapy using oncolytic viruses alongside standard cancer treatment methods and other immunotherapy-based treatments can expect more promising results in the future.

Identifiants

pubmed: 37797673
pii: S0014-2999(23)00575-7
doi: 10.1016/j.ejphar.2023.176063
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

176063

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Seyed-Mahmood Seyed-Khorrami (SM)

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Arezou Azadi (A)

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Nasrin Rastegarvand (N)

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Ala Habibian (A)

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.

Hoorieh Soleimanjahi (H)

Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Electronic address: soleim_h@modares.ac.ir.

Marek J Łos (MJ)

Biotechnology Center, Silesian University of Technology, 8 Krzywousty St., 44-100, Gliwice, Poland; LinkoCare Life Sciences AB, Linkoping, Sweden. Electronic address: marek.los@polsl.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH